11 Oct Crystal Meth: Is Wipe Sampling Adequate to Determine if Occupants Have Been Breaking Bad?
MedicalResearch.com Interview with: [caption id="attachment_51821" align="alignleft" width="200"]
Crystal MethWikipedia image[/caption] Dr Jackie Wright (Fellow ACTRA) Adjunct – Flinders UniversityDirector Environmental Risk Sciences (enRiskS) MedicalResearch.com: What is the background for this study? Response: The contamination of homes with methamphetamine can occur from illegal manufacture or smoking (ice). The methamphetamine residues that are left behind can result in methamphetamine exposures to future occupants of the home, resulting in the potential for adverse health effects. To assess the level of contamination that remains in these homes, the method used is to collect a surface wipe sample. This is a wipe of specified area of a surface (such as walls, floors, kitchen cabinets, or window frames etc) which is then analysed to determine how much methamphetamine residue remain on that surface. The guidelines for determining if a property is safe for occupation is based on surface wipe sampling. This study has further evaluated the level of methamphetamine that is present in a home that was formerly suspected to have been used for the manufacture of methamphetamine. To supplement surface wipe sampling which was undertaken over time, the level of methamphetamine that is within the building/house materials/items themselves was tested, as a bulk analysis, to determine how much methamphetamine is present in these materials, if the methamphetamine has penetrated through and into materials such as the gyprock walls, and if the methamphetamine that is present in materials present when the manufacture occurred have transferred to the homeowners possessions that were brought into the home well after manufacture occurred.
Dr. Hongying (Daisy) Dai[/caption]
Hongying (Daisy) Dai, PhD
Associate Professor
Department of Biostatistics | College of Public Health
University of Nebraska Medical Center
MedicalResearch.com: What is the background for this study?
Response: Although marijuana is still classified as a Schedule I drug at the Federal level, as of June 2019, 33 states and the District of Columbia have legalized one or more forms of marijuana; 11 states and the District of Columbia have approved both medical and recreational uses. Public opinion on marijuana has changed dramatically over the last two decades and support for legalization has doubled since 2010. However, very little is known about the prevalence and patterns of marijuana use among adults with medical conditions.
This study analyzed the 2016 and 2017 Behavioral Risk Factor Surveillance System data to report the prevalence and patterns of marijuana use among adults with self-reported medical conditions.


Dr. Gery Guy[/caption]
Gery P. Guy Jr., PhD, MPH
Senior Health Economist
Division of Unintentional Injury Prevention
CDC
MedicalResearch.com: What is the background for this study?
Response: In 2017, among the 70,237 drug overdose deaths in the United States, 47,600 (67.8%) involved prescription or illicit opioids. Distribution of the opioid receptor antagonist naloxone to reverse overdose is a key part of the public health response to the opioid overdose epidemic. The 2016 CDC Guideline for Prescribing Opioids for Chronic Pain recommended clinicians consider offering naloxone when overdose risk factors, such as history of overdose or opioid use disorder, higher opioid dosages, or concurrent benzodiazepine use, are present.
However, recent analyses examining pharmacy-based naloxone dispensing are lacking. To address this gap and to inform future overdose prevention and response efforts, CDC examined trends and characteristics of naloxone dispensed from retail pharmacies at the national and county level in the United States.
